Now showing items 28-47 of 84

      EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood [1]
      The elusive definition of pandemic influenza [1]
      EMA recommendation on hydroxyethyl starch solutions obscured controversy [1]
      EMA scales back transparency initiatives because of workload [1]
      Ensuring safe and effective drugs: who can do what it takes? [1]
      The evidence base for new drugs [1]
      FDA drug summaries: a simplification too far? [1]
      FDA to begin releasing clinical study reports in pilot programme [1]
      FDA unease about faster drug approval [1]
      From promises to policies: is big pharma delivering on transparency? [1]
      The imperative to share clinical study reports: recommendations from the Tamiflu experience [1]
      Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial [1]
      “Independent” reanalysis of landmark starch solutions trial was published by original authors [1]
      Influenza vaccination of health care workers [1]
      Influenza vaccination: policy versus evidence [1]
      Influenza: marketing vaccine by marketing disease [1]
      Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011 [1]
      Integrated Drug Reviews at the US Food and Drug Administration-Legal Concerns and Knowledge Lost. [1]
      Integrated Drug Reviews at the US Food and Drug Administration-Reply [1]
      Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review [1]